Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
UBS
Farmers Insurance
Chinese Patent Office
Medtronic
Moodys
Daiichi Sankyo
Express Scripts
Fish and Richardson
Julphar

Generated: February 17, 2018

DrugPatentWatch Database Preview

Desvenlafaxine succinate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for desvenlafaxine succinate and what is the scope of desvenlafaxine succinate freedom to operate?

Desvenlafaxine succinate
is the generic ingredient in two branded drugs marketed by Actavis Labs Fl, Alembic Pharms Ltd, Lupin Ltd, Mylan Pharms Inc, Sandoz Inc, West-ward Pharms Int, Zydus Pharms Usa Inc, and Wyeth Pharms Inc, and is included in nine NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Desvenlafaxine succinate has sixty-eight patent family members in thirty-two countries.

There are sixteen drug master file entries for desvenlafaxine succinate. Fourteen suppliers are listed for this compound.
Summary for desvenlafaxine succinate
Medical Subject Heading (MeSH) Categories for desvenlafaxine succinate

US Patents and Regulatory Information for desvenlafaxine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204172-002 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Alembic Pharms Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204003-002 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Alembic Pharms Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204003-001 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
West-ward Pharms Int DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204082-001 Feb 16, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
West-ward Pharms Int DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204083-001 Feb 16, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sandoz Inc DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204028-001 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sandoz Inc DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204028-002 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-003 Jul 29, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204172-001 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204095-001 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for desvenlafaxine succinate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508 Succinate salt of O-desmethyl-venlafaxine ➤ Sign Up
7,291,347 Succinate salt of O-desmethyl-venlafaxine ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for desvenlafaxine succinate

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Healthtrust
Harvard Business School
Accenture
Baxter
Fish and Richardson
Boehringer Ingelheim
Citi
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot